Document Detail


A critical appraisal of the cardiac arrhythmia suppression trial (CAST).
MedLine Citation:
PMID:  10147539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The presence of ventricular ectopic activity in the post-myocardial infarction patient, especially associated with left ventricular dysfunction, has been associated with a high incidence of sudden cardiac death. To test the PVC hypothesis, that PVC suppression in asymptomatic patients with ventricular arrhythmias post-myocardial infarction might reduce sudden death rate, the cardiac arrhythmia suppression trial (CAST) was performed. In patients treated with encainide or flecainide, total mortality at 10 months was 7.7% compared to only 3% overall mortality on placebo. The increase in mortality and sudden cardiac death with these two drugs raised the question of whether PVC suppression in this group of patients should be attempted. In addition, the extrapolation of the results of this study to other patient groups has resulted in a change of our antiarrhythmic prescription habits. Criticism of the CAST study has included a low placebo mortality, which may have been secondary to entry of low-risk groups of patients, deaths in the open label titration groups not being included, and recent advances in thrombolysis and revascularization. In addition, this low placebo mortality may have been explained by the concept that drug-responsive arrhythmias may have more benign prognosis. The above results suggest that, except for the use of beta blockers, benefits of other anti-arrhythmic drug treatment in the post-infarction patient with asymptomatic benign and potentially lethal ventricular arrhythmias is questionable. Flecainide and encainide should be avoided in this group of patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
G V Naccarelli; A H Dougherty; D Wolbrette; S Wiggins
Related Documents :
3621279 - Differential utility of antiarrhythmic agents.
15965569 - Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery di...
8498299 - Autonomic correlates of late infarct artery patency after first myocardial infarction.
23385679 - Pattern of congenital heart disease in ilorin, nigeria.
2277409 - Prospective study of late potentials to predict cardiac sudden death and ventricular ta...
1550019 - Survival after implantation of the cardioverter defibrillator.
15093979 - Preinfarction angina does not alter infarct size and in hospital outcome after acute my...
12370689 - Risk factors associated with acute lower extremity ischemia after coronary revasculariz...
19522959 - Sudden cardiac arrest in patients with severe nonischemic heart failure: risk stratific...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Applied cardiopulmonary pathophysiology : ACP     Volume:  4     ISSN:  0920-5268     ISO Abbreviation:  Appl Cardiopulm Pathophysiol     Publication Date:  1991  
Date Detail:
Created Date:  1992-11-25     Completed Date:  1992-11-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8801258     Medline TA:  Appl Cardiopulm Pathophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  9-16     Citation Subset:  T    
Affiliation:
The Electrophysiology Laboratory, Division of Cardiology, University of Texas Medical School at Houston.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arrhythmias, Cardiac / drug therapy*,  mortality
Clinical Trials as Topic*
Encainide / therapeutic use
Flecainide / therapeutic use
Humans
Imipramine / therapeutic use
Moricizine / therapeutic use
Multicenter Studies as Topic
Pilot Projects
Randomized Controlled Trials as Topic
Risk Factors
Chemical
Reg. No./Substance:
31883-05-3/Moricizine; 50-49-7/Imipramine; 54143-55-4/Flecainide; 66778-36-7/Encainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The influence of curing time and environment on the fracture properties of bone cement.
Next Document:  Surgical and catheter ablative techniques for treating supraventricular tachycardia.